Biocryst Pharmaceuticals’s Influenza Drug Shows Promise in Study

Reuters -- BioCryst Pharmaceuticals said a late-stage study testing the intravenous form of its experimental influenza drug peramivir showed the drug was not inferior to another flu drug, Tamiflu.